| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | VANDA PHARMACEUTICALS INC COM | 1,918,929 | 17,865,000 | 20.93% | ||
| 2 | CTI BIOPHARMA CORP | 10,698,618 | 13,159,000 | 15.42% | ||
| 3 | SCICLONE PHARMACEUTICALS INC COM | 1,175,574 | 10,815,000 | 12.67% | ||
| 4 | TOBIRA THERAPEUTICS INC | 833,377 | 8,375,000 | 9.81% | ||
| 5 | SAGENT PHARMACEUTICALS INC | 462,824 | 7,364,000 | 8.63% | ||
| 6 | PERNIX THERAPEUTICS HLDGS IN | 2,484,649 | 7,330,000 | 8.59% | ||
| 7 | PAIN THERAPEUTICS INC | 3,575,000 | 6,256,000 | 7.33% | ||
| 8 | FOUNDATION MEDICINE INC COM | 173,049 | 3,644,000 | 4.27% | ||
| 9 | VERICEL CORP | 1,376,887 | 3,552,000 | 4.16% | ||
| 10 | ENANTA PHARMACEUTICALS INC COM | 71,147 | 2,349,000 | 2.75% | ||
| 11 | DERMA SCIENCES INC COM PAR .01 | 507,799 | 2,321,000 | 2.72% | ||
| 12 | CUTERA INC COM | 100,000 | 1,279,000 | 1.50% | ||
| 13 | SOCIETAL CDMO INC | 116,901 | 1,052,000 | 1.23% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001140361-16-051710, filed 2016.02.11).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
